Clinical Observation of Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy with Lobaplatin and Docetaxel on Peritoneal Carcinoma

Objective To investigate the perioperative safety and efficacy of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy(HIPEC) with lobaplatin (LBP) and docetaxel (TXT) on peritoneal carcinoma(PC) patients. Methods PC patients were treated with CRS+HIPEC using LBP 50 mg/m² and TXT 60 mg/m² in 12000 ml of normal saline at (43±0.5)℃ for 60 min. Body temperature and heart rate were recorded for 6 d after CRS plus HIPEC. Perioperative adverse events, hematological, hepatic, renal and electrolytes parameters, patients recovery and survival outcomes were analyzed. Results 90 PC patients were treated with 95 CRS plus HIPEC procedures, with the median duration of 485 min (180-450 min). The highest temperature and heart rate during six postoperative days were 36.4-38.6℃(median 37.5℃) and 76-124 bpm(median 100 bpm), respectively. Severe adverse events occurred in 16 patients, including two patients died during perioperation. The median OS was 20.8 months (95% CI: 13.1-25.8 months), and the 1-, 3-, 5-year survival rates were 75.6%, 45.6%, 43.3%, respectively. Conclusion CRS+HIPEC with LBP and TXT to treat PC is a feasible procedure with acceptable safety, and could prolong patients' survival.